London-listed RWS has added British finance expert Candida “Candy” Davies to its board and executive team as Chief Financial Officer, the company announced on July 5, 2022.
The announcement comes less than a month after the firm released mixed results for the first half of 2022 with its strength in life sciences being offset by weakening demand for patent services as a result of the EU Unitary Patent.
Davies has an extensive background in the healthcare and health technology industries, including positions at global giants Reckitt Benckiser Group, Eli Lilly and, most recently, as Head of Finance in the Personal Health Division of Philips.
About her new appointment, Davies said she is looking forward to joining RWS and working with the leadership team on the company’s medium-term growth strategy. She will succeed Rod Day, Interim CFO, who will hand over operations to Davies in October 2022 and is expected to transition out of the company by the end of the year.
In a regulatory announcement on the new appointee, CEO Ian El-Mokadem highlighted Davies’ credentials in international, blue-chip, and health tech companies along with her financial expertise as “invaluable to the Board and the Executive team, as we continue to focus on delivering our accelerated growth plan.”
Growth plans communicated last month to RWS shareholders include two key opportunities for its Language Services division in e-learning and data services.